Company news
Alpha Cognition Inc. news in 2026
Alpha Cognition Inc.'s news releases, calls and decks from 2026, newest first.
Alpha Cognition to Report Third Quarter 2026 Financial Results and Provide Business Update
November 2, 2026
Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®
October 13, 2026
Alpha Cognition to Present New ZUNVEYL (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress
October 6, 2026
Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress
October 6, 2026
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care
October 1, 2026
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26
August 17, 2026
Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update
August 13, 2026
Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update
August 3, 2026
Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease
July 29, 2026
Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit
July 10, 2026
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
June 23, 2026
Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer’s Disease
June 16, 2026
Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer’s Disease
June 8, 2026
Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update
May 14, 2026
Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026
April 28, 2026
Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences
April 27, 2026
Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig
April 20, 2026
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 14, 2026
Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury
March 31, 2026
Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update
March 25, 2026
Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026
March 12, 2026
Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer’s Association International Conferences
March 9, 2026
Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study
February 25, 2026
Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens
February 18, 2026
Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution
January 7, 2026
Calls in 2026
Decks in 2026
- Investor Presentation (September 2026)
Investor deck · 23 slides · September 2026